Author: Gulli Arnason

REYKJAVIK, ICELAND – February 11, 2026 – Arctic Therapeutics (ATx) today announced that the first patients have been enrolled in a Phase IIa randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of topical AT-004 in patients with acne vulgaris (AV). The study follows regulatory approval from the European Medicines Agency (EMA) in December…

The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 in patients diagnosed with Alzheimer’s disease EMA grants Orphan Drug Designation (ODD) to AT-001 for hereditary cystatin C amyloid angiopathy (HCCAA), a rare familial dementia   REYKJAVIK, ICELAND – November 3, 2025 – Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company,…

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia. N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is…